Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives
暂无分享,去创建一个
[1] A. Schoenenberger,et al. Analysis of fragmented oxidized phosphatidylcholines in human plasma using mass spectrometry: Comparison with immune assays. , 2019, Free radical biology & medicine.
[2] B. Beutler,et al. Platelet-activating factor (PAF) mediates NLRP3-NEK7 inflammasome induction independently of PAFR , 2019, The Journal of experimental medicine.
[3] Aaron M. Walsh,et al. Caprine milk fermentation enhances the antithrombotic properties of cheese polar lipids , 2019, Journal of Functional Foods.
[4] A. Pitt,et al. A Targeted Mass Spectrometry Approach to detect and quantify Oxidised Phospholipids in plasma samples of Diabetic patients , 2019 .
[5] I. Zabetakis,et al. Bioprospecting for Antithrombotic Polar Lipids from Salmon, Herring, and Boarfish By-Products , 2019, Foods.
[6] J. Mullol,et al. Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications , 2019, Journal of clinical medicine.
[7] Ying Jin,et al. Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis , 2019, Journal of the American Heart Association.
[8] J. Travers. Platelet-Activating Factor as an Effector for Environmental Stressors. , 2019, Handbook of experimental pharmacology.
[9] I. Zabetakis,et al. Total, Neutral, and Polar Lipids of Brewing Ingredients, By-Products and Beer: Evaluation of Antithrombotic Activities , 2019, Foods.
[10] P. Foster,et al. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome , 2019, Mucosal Immunology.
[11] E. Fragopoulou,et al. Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism: a randomised, double-blind and placebo-controlled trial , 2019, British Journal of Nutrition.
[12] I. Zabetakis,et al. The in vitro antithrombotic properties of ale, lager, and stout beers , 2019, Food Bioscience.
[13] Aaron M. Walsh,et al. The effect of ovine milk fermentation on the antithrombotic properties of polar lipids , 2019, Journal of Functional Foods.
[14] F. Parveen,et al. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases , 2019, International journal of molecular sciences.
[15] Andrés J. García,et al. TNFα promotes mucosal wound repair through enhanced Platelet Activating Factor Receptor signaling in the epithelium , 2019, Mucosal Immunology.
[16] John O. Marentette,et al. Cigarette smoking promotes bladder cancer via increased platelet‐activating factor , 2019, Physiological reports.
[17] R. Stevens,et al. Emerging structural biology of lipid G protein‐coupled receptors , 2019, Protein science : a publication of the Protein Society.
[18] I. Zabetakis,et al. The Impact of Nutrition and Statins on Cardiovascular Diseases , 2019, Journal of Nutrition Education and Behavior.
[19] I. Zabetakis,et al. The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment. , 2019, Advances in nutrition.
[20] D. Goodenowe,et al. Plasmalogen deficiency and neuropathology in Alzheimer's disease: Causation or coincidence? , 2019, Alzheimer's & dementia.
[21] Constantina Nasopoulou,et al. In Vitro Antithrombotic Properties of Salmon (Salmo salar) Phospholipids in a Novel Food-Grade Extract , 2019, Marine drugs.
[22] A. Tierney,et al. Diet and Cardiovascular Disease: The Mediterranean Diet , 2019, The Impact of Nutrition and Statins on Cardiovascular Diseases.
[23] Constantina Nasopoulou,et al. The Anti-inflammatory Properties of Food Polar Lipids , 2019, Bioactive Molecules in Food.
[24] Hui Zhang,et al. Structural basis for ligand recognition of the human thromboxane A2 receptor , 2018, Nature Chemical Biology.
[25] S. Nolan,et al. In vitro Anti‐atherogenic Properties of N‐Heterocyclic Carbene Aurate(I) Compounds , 2018, ChemMedChem.
[26] Constantina Nasopoulou,et al. Phospholipids of goat and sheep origin: Structural and functional studies , 2018, Small Ruminant Research.
[27] Wenjing Zhang,et al. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40 , 2018, PloS one.
[28] Alex C. Bissember,et al. Progress in the Development of Platelet‐Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases , 2018, ChemMedChem.
[29] Hualiang Jiang,et al. Structural basis for signal recognition and transduction by platelet-activating-factor receptor , 2018, Nature Structural & Molecular Biology.
[30] Constantina Nasopoulou,et al. Structural Elucidation of Irish Organic Farmed Salmon (Salmo salar) Polar Lipids with Antithrombotic Activities , 2018, Marine drugs.
[31] I. Zabetakis,et al. Inflammation, not Cholesterol, Is a Cause of Chronic Disease , 2018, Nutrients.
[32] E. Brǎiloiu,et al. Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells , 2018, Neuroscience.
[33] J. McHowat,et al. PAF Expression in Skin Tumors of Smokers and Never Smokers: a Potential Role in Skin Cancer Development , 2018 .
[34] Robert P. Lennon,et al. State of the Heart: An Overview of the Disease Burden of Cardiovascular Disease from an Epidemiologic Perspective. , 2018, Primary care.
[35] J. Broach,et al. A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment , 2018, Front. Neurol..
[36] S. Jancar,et al. Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death , 2018, Front. Oncol..
[37] A. Kadioglu,et al. E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells , 2018, European Respiratory Journal.
[38] B. Payrastre,et al. The importance of blood platelet lipid signaling in thrombosis and in sepsis. , 2017, Advances in biological regulation.
[39] I. Zabetakis,et al. Phospholipids of Animal and Marine Origin: Structure, Function, and Anti-Inflammatory Properties , 2017, Molecules.
[40] P. Erne,et al. Pleiotropic effects of oxidized phospholipids. , 2017, Free radical biology & medicine.
[41] I. Zabetakis,et al. Invited review: The anti-inflammatory properties of dairy lipids. , 2017, Journal of dairy science.
[42] E. Fragopoulou,et al. Postprandial effects of wine consumption on Platelet Activating Factor metabolic enzymes. , 2017, Prostaglandins & other lipid mediators.
[43] A new player in interstitial cystitis/bladder pain syndrome: platelet‐activating factor – PAF and its connection to smoking , 2017, Physiological reports.
[44] E. Walters,et al. Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease. , 2017, Microbiology.
[45] E. Tsilibary,et al. A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties? , 2017, Bioinorganic chemistry and applications.
[46] T. Abe,et al. Relief from neuropathic pain by blocking of the platelet-activating factor–pain loop , 2017, The FASEB Journal.
[47] J. Nolan,et al. Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients , 2017, Free radical biology & medicine.
[48] Treesa P. Varghese,et al. Platelet activating factor: A potential biomarker in acute coronary syndrome? , 2017, Cardiovascular therapeutics.
[49] X. Yin,et al. Loss of PAFR prevents neuroinflammation and brain dysfunction after traumatic brain injury , 2017, Scientific Reports.
[50] M. Dermiki,et al. Evaluation of sensory and in vitro anti-thrombotic properties of traditional Greek yogurts derived from different types of milk , 2017, Heliyon.
[51] R. Chammas,et al. Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy , 2017, Oncogenesis.
[52] L. Shields,et al. Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases , 2017, Molecular Neurobiology.
[53] E. Walters,et al. Does upregulated host cell receptor expression provide a link between bacterial adhesion and chronic respiratory disease? , 2016, Journal of Translational Medicine.
[54] D. Ford,et al. Platelet-Activating Factor Quantification Using Reversed Phase Liquid Chromatography and Selected Reaction Monitoring in Negative Ion Mode , 2016, Lipids.
[55] M. Lahiri,et al. Platelet activating factor leads to initiation and promotion of breast cancer , 2016 .
[56] H. Chap. Forty five years with membrane phospholipids, phospholipases and lipid mediators: A historical perspective. , 2016, Biochimie.
[57] M. Philippova,et al. Hormetic and anti-inflammatory properties of oxidized phospholipids. , 2016, Molecular aspects of medicine.
[58] E. Walters,et al. Platelet‐activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients , 2016, Respirology.
[59] A. Salajegheh. Angiogenesis in Health, Disease and Malignancy , 2016, Springer International Publishing.
[60] J. Travers,et al. Radiation therapy generates platelet-activating factor agonists , 2016, Oncotarget.
[61] M. Xanthopoulou,et al. Wine consumption reduced postprandial platelet sensitivity against platelet activating factor in healthy men , 2016, European Journal of Nutrition.
[62] A. Dziekońska,et al. Effects of the platelet-activating factor (PAF) on selected quality parameters of cryopreserved bull semen (AI) with reduced sperm motility. , 2016, Polish journal of veterinary sciences.
[63] M. J. Bellizzi,et al. Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis , 2016, The Journal of Neuroscience.
[64] S. Mallik,et al. Biomarkers and Targeted Therapy in Pancreatic Cancer , 2016, Biomarkers in cancer.
[65] D. Gozal,et al. Attenuated Reactive Gliosis and Enhanced Functional Recovery Following Spinal Cord Injury in Null Mutant Mice of Platelet-Activating Factor Receptor , 2015, Molecular Neurobiology.
[66] Emerging Trends in Retrograde Signaling , 2016, Molecular Neurobiology.
[67] K. Pałgan,et al. Platelet activating factor in allergies , 2015, International journal of immunopathology and pharmacology.
[68] D. Badyal,et al. Levocetirizine and rupatadine in chronic idiopathic urticaria , 2015, International journal of dermatology.
[69] M. Lazanas,et al. The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. , 2015, AIDS reviews.
[70] Alexandre P. Blanchard,et al. Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study , 2015, Neuropsychiatric disease and treatment.
[71] Tracy E. Macaulay,et al. Platelet Activating Factor , 2015 .
[72] S. Watson,et al. The role of platelets in the recruitment of leukocytes during vascular disease , 2015, Platelets.
[73] T. Isah. Rethinking Ginkgo biloba L.: Medicinal uses and conservation , 2015, Pharmacognosy reviews.
[74] R. Korstanje,et al. The role of platelet-activating factor in mesangial pathophysiology. , 2015, The American journal of pathology.
[75] K. Uzawa,et al. Lysophosphatidylcholine Acyltransferase1 Overexpression Promotes Oral Squamous Cell Carcinoma Progression via Enhanced Biosynthesis of Platelet-Activating Factor , 2015, PloS one.
[76] Alun Williams,et al. α-Synuclein-Induced Synapse Damage in Cultured Neurons Is Mediated by Cholesterol-Sensitive Activation of Cytoplasmic Phospholipase A2 , 2015, Biomolecules.
[77] J. Bousquet,et al. Update on rupatadine in the management of allergic disorders , 2015, Allergy.
[78] Smaragdi Antonopoulou,et al. Mediterranean Diet and Its Protective Mechanisms against Cardiovascular Disease: An Insight into Platelet Activating Factor (PAF) and Diet Interplay , 2015 .
[79] John O. Marentette,et al. Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers. , 2014, American journal of physiology. Cell physiology.
[80] G. Zimmerman,et al. Unraveling the PAF-AH/Lp-PLA2 controversy1 , 2014, Journal of Lipid Research.
[81] G. Marathe,et al. To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase , 2014, Journal of Lipid Research.
[82] Takao Shimizu,et al. Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2[S] , 2014, Journal of Lipid Research.
[83] J. Travers,et al. Systemic Platelet-activating Factor Receptor Activation Augments Experimental Lung Tumor Growth and Metastasis , 2014, Cancer growth and metastasis.
[84] W. Jiang,et al. The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy , 2014, British Journal of Cancer.
[85] P. Pais,et al. Darapladib for preventing ischemic events in stable coronary heart disease. , 2014, The New England journal of medicine.
[86] Y. Uezono,et al. Palliation of Bone Cancer Pain by Antagonists of Platelet-Activating Factor Receptors , 2014, PloS one.
[87] A. Yamashita,et al. Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms. , 2014, Progress in lipid research.
[88] Y. Uezono,et al. Pain‐releasing action of Platelet‐activating factor (PAF) antagonists in neuropathic pain animal models and the mechanisms of action , 2013, European journal of pain.
[89] Takao Shimizu,et al. Generation of membrane diversity by lysophospholipid acyltransferases. , 2013, Journal of biochemistry.
[90] A. Philippopoulos,et al. Synthesis, biochemical evaluation and molecular modeling studies of novel rhodium complexes with nanomolar activity against Platelet Activating Factor. , 2013, Journal of inorganic biochemistry.
[91] T. Nomikos,et al. Platelet Activating Factor in Heart Failure: Potential Role in Disease Progression and Novel Target for Therapy , 2013, Current Heart Failure Reports.
[92] A. Tsoupras,et al. Paricalcitol Effects on Activities and Metabolism of Platelet Activating Factor and on Inflammatory Cytokines in Hemodialysis Patients , 2013, The International journal of artificial organs.
[93] G. Liss,et al. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. , 2008, The Journal of allergy and clinical immunology.
[94] R. G. Salomon. Structural Identification and Cardiovascular Activities of Oxidized Phospholipids , 2012, Circulation research.
[95] R. Rosenson,et al. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2 , 2012, Journal of Lipid Research.
[96] M. Lazanas,et al. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. , 2012, AIDS research and human retroviruses.
[97] J. Grigg. The platelet activating factor receptor: a new anti-infective target in respiratory disease? , 2012, Thorax.
[98] M. Lazanas,et al. Platelet-Activating Factor and Its Basic Metabolic Enzymes in Blood of Naive HIV-Infected Patients , 2012, Angiology.
[99] R. Wood‐Baker,et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells , 2012, Thorax.
[100] R. Chammas,et al. Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma , 2012, Mediators of inflammation.
[101] D. Panagiotakos,et al. Mediterranean wild plants reduce postprandial platelet aggregation in patients with metabolic syndrome. , 2012, Metabolism: clinical and experimental.
[102] Karen Y. Stokes,et al. Platelets: a critical link between inflammation and microvascular dysfunction , 2012, The Journal of physiology.
[103] J. Travers,et al. Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis. , 2012, Carcinogenesis.
[104] M. Lazanas,et al. Effects of Highly Active Antiretroviral Therapy on Platelet Activating Factor Metabolism in Naïve HIV-Infected Patients: II) Study of the Abacavir/Lamivudine/Efavirenz Haart Regimen , 2012, International journal of immunopathology and pharmacology.
[105] F. Gómez,et al. Platelet-Activating Factor Antagonists , 2000, BioDrugs.
[106] Constantina Nasopoulou,et al. Fish polar lipids retard atherosclerosis in rabbits by down-regulating PAF biosynthesis and up-regulating PAF catabolism , 2011, Lipids in Health and Disease.
[107] H. Tozaki-Saitoh,et al. Platelet-activating factor and pain. , 2011, Biological & pharmaceutical bulletin.
[108] A. Tsoupras,et al. In Vitro and In Vivo Effects of Statins on Platelet-Activating Factor and Its Metabolism , 2011, Angiology.
[109] V. Ingham,et al. Inhibition of phospholipase A2 increased the removal of the prion derived peptide PrP82-146 from cultured neurons , 2011, Neuropharmacology.
[110] F. Cunha,et al. Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice , 2011, Cancer Chemotherapy and Pharmacology.
[111] D. Iliopoulos,et al. Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[112] Qiaofang Yi,et al. Ultraviolet B Radiation of Human Skin Generates Platelet‐activating Factor Receptor Agonists , 2010, Photochemistry and photobiology.
[113] A. Weyrich,et al. The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. , 2010, Biochimie.
[114] D. Iliopoulos,et al. In vivo anti-atherogenic properties of cultured gilthead sea bream (Sparus aurata) polar lipid extracts in hypercholesterolaemic rabbits. , 2010 .
[115] Takao Shimizu,et al. Role of PAF Receptor in Proinflammatory Cytokine Expression in the Dorsal Root Ganglion and Tactile Allodynia in a Rodent Model of Neuropathic Pain , 2010, PloS one.
[116] V. Bochkov,et al. Generation and biological activities of oxidized phospholipids. , 2010, Antioxidants & redox signaling.
[117] Alun Williams,et al. Phospholipase A2 inhibitors protect against prion and Aβ mediated synapse degeneration , 2010, Molecular Neurodegeneration.
[118] S. Nonogaki,et al. Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy , 2010, BMC Cancer.
[119] A. Tsoupras,et al. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. , 2009, Infectious disorders drug targets.
[120] M. Bar‐eli,et al. Inflammation and melanoma metastasis , 2009, Pigment cell & melanoma research.
[121] X. Chen,et al. Platelet Activation by Low Concentrations of Intact Oxidized LDL Particles Involves the PAF Receptor , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[122] K. Birukov,et al. Oxidized phospholipids in control of inflammation and endothelial barrier , 2009, Translational Research.
[123] D. Panagiotakos,et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. , 2009, Clinical biochemistry.
[124] D. Stafforini. Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2) , 2009, Cardiovascular Drugs and Therapy.
[125] Frits Mastik,et al. Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.
[126] M. Lazanas,et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? , 2008, AIDS research and human retroviruses.
[127] G. Panayotou,et al. BIOACTIVE POLAR LIPIDS IN OLIVE OIL, POMACE AND WASTE BYPRODUCTS , 2008 .
[128] M. Hanefeld,et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. , 2008, Journal of the American College of Cardiology.
[129] J. Bousquet,et al. Rupatadine in allergic rhinitis and chronic urticaria , 2008, Allergy.
[130] D. Loutradis,et al. Intravenous infusion of PAF affects ovulation, fertilization and preimplantation embryonic development in NZB x NZW F1 hybrid mice. , 2008, Prostaglandins & other lipid mediators.
[131] M. Bar‐eli,et al. Emerging Roles of PAR-1 and PAFR in Melanoma Metastasis , 2008, Cancer Microenvironment.
[132] A. Oliver,et al. Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells. , 2008, The Journal of infectious diseases.
[133] B. Rogala,et al. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. , 2008, Recent patents on inflammation & allergy drug discovery.
[134] B. Rogala,et al. Platelet Activating Factor as a Mediator and Therapeutic Approach in Bronchial Asthma , 2008, Inflammation.
[135] Alun Williams,et al. Ginkgolides protect against amyloid-β1–42-mediated synapse damage in vitro , 2008, Molecular Neurodegeneration.
[136] M. Bar‐eli,et al. Inflammation and melanoma growth and metastasis: The role of platelet-activating factor (PAF) and its receptor , 2007, Cancer and Metastasis Reviews.
[137] D. Iliopoulos,et al. Antithrombotic and Antiatherosclerotic Properties of Olive Oil and Olive Pomace Polar Extracts in Rabbits , 2007, Mediators of inflammation.
[138] A. Hermetter,et al. Oxidized phospholipids: from molecular properties to disease. , 2007, Biochimica et biophysica acta.
[139] T. Nomikos,et al. Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase, of Human Mesangial Cells , 2007, Mediators of inflammation.
[140] V. Bochkov. Inflammatory profile of oxidized phospholipids , 2007, Thrombosis and Haemostasis.
[141] A. Mourelatos,et al. Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. , 2006, Journal of medicinal food.
[142] F. Labrousse,et al. Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma. , 2006, World journal of gastroenterology.
[143] E. Fragopoulou,et al. Effect of fast-food Mediterranean-type diet on type 2 diabetics and healthy human subjects' platelet aggregation. , 2006, Diabetes research and clinical practice.
[144] D. Iliopoulos,et al. In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[145] Shi-hai Xia,et al. Role of platelet-activating factor in pathogenesis of acute pancreatitis , 2006 .
[146] A. Evangelou,et al. Inhibition by cardiolipins of platelet-activating factor-induced rabbit platelet activation , 1993, Lipids.
[147] Y. Naito,et al. Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes , 1991, Lipids.
[148] E. Fragopoulou,et al. Characterization of Acetyl-CoA: Lyso-PAF Acetyltransferase of Human Mesangial Cells , 2005, Mediators of inflammation.
[149] J. Travers,et al. Ultraviolet B Radiation Generates Platelet-activating Factor-like Phospholipids underlying Cutaneous Damage* , 2005, Journal of Biological Chemistry.
[150] C. O'neill. The role of paf in embryo physiology. , 2005, Human reproduction update.
[151] Subodh Kumar,et al. Platelet activating factor improves the in vitro penetration of zona free hamster eggs by buffalo (Bubalus bubalis) spermatozoa. , 2005, Theriogenology.
[152] P. Braquet,et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba , 2005, Agents and Actions.
[153] J. Conard,et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin , 2005, Agents and Actions.
[154] J. Benveniste. Jacques Benveniste , 2004, BMJ : British Medical Journal.
[155] B. Aggarwal,et al. Nuclear factor-kappaB: a friend or a foe in cancer? , 2004, Biochemical pharmacology.
[156] N. Bazan,et al. Interplay among platelet‐activating factor, oxidative stress, and group I metabotropic glutamate receptors modulates neuronal survival , 2004, Journal of neuroscience research.
[157] D. Lewis,et al. Augmentation of Chemotherapy-Induced Cytokine Production by Expression of the Platelet-Activating Factor Receptor in a Human Epithelial Carcinoma Cell Line1 , 2004, The Journal of Immunology.
[158] M. Mathonnet,et al. Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer. , 2004, Mediators of inflammation.
[159] I. Izquierdo,et al. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. , 2004, Journal of investigational allergology & clinical immunology.
[160] Smaragdi Antonopoulou,et al. Platelet activating factor — a molecular link between atherosclerosis theories , 2003 .
[161] G. Baltas,et al. Hydroxyl-platelet-activating factor exists in blood of healthy volunteers and periodontal patients. , 2003, Mediators of inflammation.
[162] P. Halligan,et al. Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist , 2003, Heart.
[163] L. Kemény,et al. Platelet-Activating Factor Antagonist WEB 2086 Inhibits Ultraviolet-B Radiation-Induced Dermatitis in the Human Skin , 2003, Skin Pharmacology and Physiology.
[164] A. Tselepis,et al. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.
[165] J. Witztum,et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[166] F. Gruber,et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage , 2002, Nature.
[167] G. Zimmerman,et al. Activation of vascular cells by PAF-like lipids in oxidized LDL. , 2002, Vascular pharmacology.
[168] K. Shimizu,et al. Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). , 2002, Bioorganic & medicinal chemistry letters.
[169] P. Libby,et al. Inflammation and Atherosclerosis , 2002, Circulation.
[170] J. Eckman,et al. Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. , 2001, Pharmacological research.
[171] D. Fatovich,et al. Platelet-activating factor antagonism and streptokinase-induced hypotension in clinical acute myocardial infarction. , 2001, Clinical science.
[172] I. Jantan,et al. Inhibitory effects of xanthones on platelet activating factor receptor binding in vitro. , 2001, Journal of ethnopharmacology.
[173] J. Heinecke,et al. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. , 2001, Trends in cardiovascular medicine.
[174] G. Zimmerman,et al. Oxidized LDL contains inflammatory PAF-like phospholipids. , 2001, Trends in cardiovascular medicine.
[175] H. Schaefers,et al. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[176] J. Neoptolemos,et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis , 2001, Gut.
[177] S Russo,et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. , 2000, The American journal of pathology.
[178] J. Lysiak,et al. Dithiolane analogs of lignans inhibit interferon-gamma and lipopolysaccharide-induced nitric oxide production in macrophages. , 2000, Acta pharmacologica Sinica.
[179] G. Zimmerman,et al. The Leukocyte Integrins* , 2000, The Journal of Biological Chemistry.
[180] T. Nomikos,et al. Separation of biologically active lipids from red wine. , 2000, Journal of agricultural and food chemistry.
[181] J. Vincent,et al. Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis , 2000, Critical care medicine.
[182] J. Simpson,et al. A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis , 2000, Antimicrobial Agents and Chemotherapy.
[183] G. Camussi,et al. Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.
[184] G. Zimmerman,et al. Platelet-activating factor and related lipid mediators. , 2000, Annual review of biochemistry.
[185] G. Ramsay,et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. , 2000, Shock.
[186] S. Ishii,et al. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. , 2000, Progress in lipid research.
[187] P. Dentelli,et al. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. , 1999, Circulation research.
[188] D. Tew,et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.
[189] F. Snyder. The ether lipid trail: a historical perspective. , 1999, Biochimica et biophysica acta.
[190] C. Hawkey,et al. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. , 1998, Gastroenterology.
[191] M. Schaller,et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.
[192] A. Sapino,et al. Potential angiogenic role of platelet-activating factor in human breast cancer. , 1998, The American journal of pathology.
[193] P. Hilliquin,et al. A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis. , 1998, The Journal of rheumatology.
[194] V. Peinado,et al. Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. , 1998, The European respiratory journal.
[195] Jung Joon Lee,et al. Platelet-activating factor antagonistic activity and13C NMR assignment of pregomisin and chamigrenal fromSchisandra chinensis , 1997, Archives of pharmacal research.
[196] J. Bian,et al. Piperbetol, methylpiperbetol, piperol A and piperol B: a new series of highly specific PAF receptor antagonists from Piper betle. , 1997, Planta medica.
[197] P. Barnes,et al. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. , 1997, American journal of respiratory and critical care medicine.
[198] Y. Hirashima,et al. Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures , 1997, Brain Research.
[199] V. I. Kulikov,et al. Ether lipids and platelet-activating factor: evolution and cellular function. , 1997, Biochemistry. Biokhimiia.
[200] Paul F. Smith,et al. PLATELET-ACTIVATING FACTOR IN THE CNS , 1996, Progress in Neurobiology.
[201] C. Semidalas,et al. Platelet-activating factor (PAF) antagonists in foods : A study of lipids with PAF or anti-PAF-like activity in cow's milk and yogurt , 1996 .
[202] A. Weyrich,et al. Activated platelets signal chemokine synthesis by human monocytes. , 1996, The Journal of clinical investigation.
[203] C. A. Demopoulos,et al. A discovery trip to compounds with PAF-like activity. , 1996, Advances in experimental medicine and biology.
[204] D. Argyropoulos,et al. Biologically active lipids from S. scombrus. , 1996, Advances in experimental medicine and biology.
[205] C. Iatrou,et al. Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet-activating factor. , 1996, The international journal of biochemistry & cell biology.
[206] H. Bito,et al. Platelet-activating factor receptor. , 2002, Journal of lipid mediators and cell signalling.
[207] R. Dean,et al. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[208] L. Formela,et al. Randomized, double‐blind phase II trial of Lexipafant, a platelet‐activating factor antagonist, in human acute pancreatitis , 1995, The British journal of surgery.
[209] M. Yamakido,et al. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.
[210] D. Albert,et al. Platelet activating factor antagonists. , 1995, Advances in pharmacology.
[211] L. McManus,et al. Lipid inhibitors of platelet-activating factor (PAF) in normal human plasma. , 1995, Journal of lipid mediators and cell signalling.
[212] K. Chung,et al. Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. , 1995, American journal of respiratory and critical care medicine.
[213] G. Zimmerman,et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.
[214] P. Braquet,et al. Platelet-activating factor antagonists , 1995, Clinical Reviews in Allergy.
[215] Fred L. Snyder. Metabolic processing of PAF , 1995, Clinical reviews in allergy.
[216] P. Kerkhof,et al. The effect of topical application of the platelet‐activating factor‐antagonist, Ro 24‐0238, in psoriasis vulgaris—a clinical and immunohistochemical study , 1994, Clinical and experimental dermatology.
[217] K. Chung,et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. , 1994, American journal of respiratory and critical care medicine.
[218] Smaragdi Antonopoulou,et al. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. , 1994, Biochimica et biophysica acta.
[219] M. Triggiani,et al. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. , 1994, The Journal of clinical investigation.
[220] P. Calverley,et al. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. , 1994, American journal of respiratory and critical care medicine.
[221] C. Semidalas,et al. PAF antagonists in foods: isolation and identification of PAF antagonists in honey and wax , 1994 .
[222] A. Evangelou. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. , 1994, Prostaglandins, leukotrienes, and essential fatty acids.
[223] R. Mcclure,et al. Effect of platelet-activating factor (PAF) on human spermatozoa-oocyte interactions. , 1993, Journal of reproduction and fertility.
[224] M. Olson,et al. Platelet-activating factor: receptors and signal transduction. , 1993, The Biochemical journal.
[225] P. O'Byrne,et al. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. , 1993, Thorax.
[226] R. P. McManus,et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. , 1993, Journal of lipid mediators.
[227] F. Valone. Quantifying platelet-activating factor in biologic systems. , 1993, The Journal of allergy and clinical immunology.
[228] C. Semidalas,et al. PAF antagonists in foods: isolation and identification of PAF antagonists in virgin olive oil , 1993 .
[229] K. P. Hui,et al. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. , 1993, The American review of respiratory disease.
[230] S. Kerwar,et al. Analogues of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor. , 1992, Journal of medicinal chemistry.
[231] H. Sarau,et al. Platelet-activating factor stimulates phosphoinositide turnover in neurohybrid NCB-20 cells: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins and inhibition by protein kinase C. , 1992, Molecular pharmacology.
[232] J. García-Rafanell,et al. Effects of PAF‐antagonists in mouse ear oedema induced by several inflammatory agents , 1991, British journal of pharmacology.
[233] D. Stafforini,et al. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.
[234] K. Hsieh. Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. , 1991, Chest.
[235] F. Bussolino,et al. Acetylcholine‐induced production of platelet‐activating factor by human fetal brain cells in culture , 1990, Journal of neuroscience research.
[236] S. Morooka,et al. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661. , 1990, Molecular pharmacology.
[237] Hwang Sb. Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990 .
[238] H. Heuer,et al. Use of WEB 2086 and WEB 2170 as platelet-activating factor antagonists. , 1990, Methods in enzymology.
[239] S. Hwang. Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990, Journal of lipid mediators.
[240] B. Minhas,et al. Effects of platelet activating factor on mouse oocyte fertilization in vitro. , 1989, American journal of obstetrics and gynecology.
[241] B. Spur,et al. Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis. , 1989, Clinical and experimental immunology.
[242] M. Rouis,et al. Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophages. , 1988, Biochemical and biophysical research communications.
[243] J. Arnout,et al. EFFECTIVENESS AND TOLERABILITY OF CV-3988, A SELECTIVE PAF ANTAGONIST, AFTER INTRAVENOUS ADMINISTRATION TO MAN , 1988, Thrombosis and Haemostasis.
[244] P. Braquet,et al. Presence of specific binding sites for platelet-activating factor (PAF) in brain. , 1988, Biochemical and biophysical research communications.
[245] Y. Imura,et al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. , 1987, The Journal of pharmacology and experimental therapeutics.
[246] D. Stafforini,et al. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. , 1987, The Journal of biological chemistry.
[247] A. Evangelou,et al. Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. , 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.
[248] B. Vargaftig,et al. PAF-acether-induced synthesis of prostacyclin by human endothelial cells. , 1986, European journal of pharmacology.
[249] J. Tomesch,et al. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. , 1986, Thrombosis and haemostasis.
[250] P. Braquet,et al. Hemodynamic effects of PAF-acether. , 1986, Pharmacological research communications.
[251] P. Braquet,et al. Thrombus induction by endogenic paf-acether and its inhibition by Ginkgo Biloba extracts in the guinea pig. , 1986, Prostaglandins.
[252] G. Camussi. Potential role of platelet-activating factor in renal pathophysiology. , 1986, Kidney international.
[253] K. Kubo,et al. Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. , 1986, Prostaglandins.
[254] P. Braquet. Proofs of involvement of PAF-acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PAF-acether antagonist isolated from Ginkgo biloba L. , 1986, Advances in prostaglandin, thromboxane, and leukotriene research.
[255] N. Andrikopoulos,et al. Biological activity of lipids of pine pollen on platelet aggregation in correlation with the platelet activating factor. , 1986, Biochemistry International.
[256] S. Hwang,et al. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. , 1985, The Journal of biological chemistry.
[257] Kathy,et al. BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L. , 1985 .
[258] M. Record,et al. Evidence that biosynthesis of platelet‐activating factor (paf‐acether) by human neutrophils occurs in an intracellular membrane , 1985, FEBS letters.
[259] G. Zimmerman,et al. Production of platelet-activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. , 1985, Circulation.
[260] X. Wang,et al. Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[261] F. Valone. Inhibition of binding of the platelet-activating factor AGEPC to platelets by the AGEPC analog rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate (CV-3988). , 1985, Biochemical and biophysical research communications.
[262] R. Lenox,et al. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. , 1984, Science.
[263] G. Zimmerman,et al. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[264] C. Page,et al. Platelet‐activating factor: a possible mediator of the dual response to allergen? , 1984, Clinical allergy.
[265] Mahendra K. Jain,et al. Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. , 1983, Thrombosis research.
[266] H. Nomura,et al. CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.
[267] J. V. Levy. Calmodulin Antagonist W-7 Inhibits Aggregation of Human Platelets Induced by Platelet Activating Factor , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[268] J. Palmer,et al. Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. , 1981, The American review of respiratory disease.
[269] F. Snyder,et al. Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. , 1981, Biochimica et biophysica acta.
[270] L. Douste-Blazy,et al. Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets , 1981, Nature.
[271] F. Snyder,et al. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). , 1981, The Journal of biological chemistry.
[272] J. Benveniste,et al. Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[273] J. Palmer,et al. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. , 1980, The American review of respiratory disease.
[274] L. McManus,et al. Complement localization and mediation of ischemic injury in baboon myocardium. , 1980, The Journal of clinical investigation.
[275] F. Bussolino,et al. Pharmacological modulation of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. , 1980, Immunology.
[276] J. Liehr,et al. Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. , 1980, The Journal of biological chemistry.
[277] L. McManus,et al. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. , 1980, Journal of immunology.
[278] N. Cusack. Platelet-activating factor , 1980, Nature.
[279] F. Snyder,et al. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. , 1979, Biochemical and biophysical research communications.
[280] D. Hanahan,et al. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.
[281] D. Hanahan,et al. Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. , 1979, Journal of immunology.
[282] B. Vargaftig,et al. The role of platelet-activating factor in platelet aggregation , 1979, Nature.
[283] J. Polonsky,et al. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. , 1979 .
[284] P. Henson,et al. Basophil-derived platelet-activating factor (PAF) as an in vivo mediator of acute allergic reactions: demonstration of specific desensitization of platelets to PAF during IgE-induced anaphylaxis in the rabbit. , 1977, Journal of immunology.
[285] J. Benveniste,et al. Structural analysis of purified platelet-activating factor by lipases , 1977, Nature.
[286] J. Benveniste,et al. Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils , 1974, Nature.
[287] P. Henson,et al. LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETS THE ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR , 1972 .
[288] A. G. Osler,et al. Destruction of rabbit platelets in the allergic response of sensitized leukocytes. I. Demonstration of a fluid phase intermediate. , 1971, Journal of immunology.
[289] A. J. Slotboom,et al. Hydrolysis of phosphoglycerides by purified lipase preparations I. Substrate-, positional- and stereo-specificity , 1970 .
[290] N. Zvaifler,et al. Antigen Induced Histamine Release from Platelets of Rabbits Producing Homologous PGA Antibody. , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[291] L. M. Deenen,et al. Structural identification of isomeric lysolecithins , 1965 .